Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Cholangiocarcinoma 5 Urinary Bladder Neoplasms 3 Acrocephalosyndactylia 3 Stomach Neoplasms 2 Glioblastoma 2 Breast Neoplasms 2 Uterine Cervical Neoplasms 1 Upper Tract Urothelial Carcinomas 1 Tumor With Alterations of the FGF-R 1 Squamous Cell Carcinoma of Head and Neck 1 Renal Pelvis and Ureter Urothelial Carcinoma 1 Rectal Neoplasms 1 Papillomavirus Infections 1 Pancreatic Neoplasms 1 Oncogenic osteomalacia 1 Neoplasms 1 Neoplasm Metastasis 1 Nasopharyngeal Neoplasms 1 Melanoma 1 Lung Neoplasms 1 Liver Neoplasms 1 Hypophosphatemia 1 Hematologic Neoplasms 1 Glioma 1 Colonic Neoplasms 1 Central Nervous System Neoplasms 1 Advanced Gastrointestinal Stromal Tumor (GIST) 1

Interventions

pembrolizumab 300 Nivolumab 273 Ipilimumab 250 aldesleukin 137 Cyclophosphamide 136 Interleukin-2 105 trametinib 82 dabrafenib 76 Temozolomide 75 Dacarbazine 74 Vemurafenib 71 fludarabine 68 fludarabine phosphate 62 Biopsy 49 binimetinib 47 sargramostim 44 Radiosurgery 44 Bevacizumab 43 Paclitaxel 42 encorafenib 40 incomplete Freund's adjuvant 39 atezolizumab 38 Radiotherapy 37 Specimen Handling 36 Cisplatin 36 CTLA-4 Antigen 36 Magnetic Resonance Spectroscopy 35 Carboplatin 35 cobimetinib 34 Introns 33

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Melanoma × infigratinib × Clear all

NCT02159066 2024-03-05

LOGIC-2

Pfizer

Phase 2 Completed

158 enrolled 40 charts

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡